Agenus Inc. — FY 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. The filing also reports fourth-quarter results. Agenus is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases, with revenue largely dependent on licensing and partner programs.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $16.0 million | $2.8 million |
| Operating loss | $6.7 million | $19.1 million |
| Net loss | $11.3 million | $23.3 million |
| Net loss attributable to common stockholders | $12.1 million; $0.51 per share | $24.1 million; $1.21 per share |
| Operating cash flow | $1.0 million provided | $16.2 million used |
| Cash and cash equivalents at year-end | $21.5 million | $10.7 million |
FY 2012 cost of revenue was $0.7 million, equivalent to an approximately 95.8% gross margin; the high margin reflects the licensing-heavy revenue mix and is not representative of a mature product business. Research and development expense was $10.6 million, down from $11.0 million; general and administrative expense was $11.5 million, up from $10.8 million. Interest expense increased to $4.7 million from $4.2 million.
At December 31, 2012, current assets were $22.6 million and current liabilities were $4.8 million. Debt principal was approximately $39.2 million, including $39.0 million of 8% senior secured convertible notes due August 2014. Total assets were $29.1 million and stockholders’ deficit was $17.6 million. The filing reports no off-balance-sheet arrangements.
Fourth-quarter 2012 revenue was $1.09 million and net loss was $5.44 million, or $5.64 million attributable to common stockholders ($0.23 per share). In fourth-quarter 2011, revenue was $0.64 million and net loss was $6.02 million.
Material changes and business developments
- Revenue rose sharply, primarily from non-recurring 2012 licensing transactions: $6.5 million recognized under an expanded GSK license and $6.25 million from an existing licensee’s buyout of a royalty stream. The filing cautions that 2012 revenue and positive operating cash flow are not indicative of future results.
- GSK paid $9.0 million under an amended agreement, including $2.5 million creditable against future royalties, and received expanded QS-21 rights plus a five-year first right to negotiate regarding a company or asset transaction.
- Operating cash flow improved from use of $16.2 million to provision of $1.0 million, mainly because of one-time license-related receipts. Financing activities included $10.5 million net proceeds from equity sales; common shares issued increased to 24.6 million from 21.5 million.
- HerpV entered a Phase 2 trial in late 2012. Two U.S. Phase 2 glioma studies were fully enrolled or completed; a randomized G-200 study was planned to begin enrolling in the first half of 2013.
- Oncophage remained approved only in Russia for intermediate-risk renal cell carcinoma; sales had been modest. Agenus licensed Russian and certain CIS development and commercial rights to NewVac.
Outlook, risks, and unusual items
- Management estimated 2013 cash use of $18–21 million and believed available resources, together with expected license and collaboration proceeds, would fund operations through 2013. The company expected to seek further financing and stated availability and terms were uncertain.
- Agenus anticipated royalties from QS-21-containing partner products beginning in 2014, subject to clinical success, regulatory approval, launch timing, and commercial sales. Four partner vaccines were in Phase 3 development; these potential royalties are not assured.
- The $39.0 million notes mature in August 2014, carry an 8% rate, and are secured by the subsidiary holding QS-21 and HerpV rights. Noteholders have conversion and other rights; repayment or refinancing could place substantial pressure on liquidity.
- Key risks include recurring losses and reliance on external capital, dependence on licensees and collaborators, clinical and regulatory uncertainty, manufacturing and patient-specific vaccine logistics, reimbursement and commercialization challenges, and competition. Agenus also disclosed that its QS-21 composition-of-matter patent had expired in most territories.
- Subsequent to year-end, Series A preferred stock was exchanged for Series A-1 preferred stock with a lower annual dividend rate (0.6325% versus 2.5%), and 666,666 common shares were issued as consideration.
- KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. The company reported no material legal proceedings.
Important facts for investors to verify
- Whether the company raised sufficient capital after the filing to fund operations beyond 2013, and the resulting dilution or financing costs.
- Current terms, outstanding balance, conversion rights, and repayment plan for the 2006 Notes before their August 2014 maturity.
- Progress and results of HerpV and glioma trials, including whether later-stage development or regulatory pathways are feasible.
- Partner trial progress, approval and launch timing, and actual royalty or milestone receipts from QS-21 programs.
- NewVac’s manufacturing readiness, reimbursement access, sales, and payments related to Oncophage in Russia and other licensed territories.
- How much of reported 2012 revenue and operating cash flow was recurring; the filing identifies significant one-time license-related contributions.